Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today ...
Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co ...
Global pharma major Lupin Limited (Lupin) announced that the United States Food and Drug Administration (FDA) has approved its ranibizumab, Ranluspec (ranibizumab-hkdz), as an interchangeable ...
European commercialization introduces an additional aflibercept biosimilar option for major retinal indications, potentially ...
The rods and cones in your eyes are responsible for helping you see, but what is responsible for helping them? Retinal pigment epithelium cells are their caretakers, but environmental, genetic and ...
Lupin advanced 1.68% to Rs 2,286.50 after the company announced that the United States Food and Drug Administration (USFDA) has approved its ranibizumab, Ranluspec (ranibizumab-hkdz) injection.
Oculis will not pursue FDA approval for OCS-01, an eye drop for diabetic macular edema, after it failed to meet the primary ...
Newly-released figures show a staggering 110 out of 111 NHS trusts that have specialist ophthalmology units in the UK failed ...
Oculis Holding AG shares plunged >35% after both Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed primary ...
Outlook Therapeutics leverages an FDA appeal victory for Lytenava amid tight finances and compliance risks. Learn why OTLK ...
Tissue engineers have developed a model to mimic the effects of aging to improve prevention and treatment of age-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results